Dabouz, Rabah
Cheng, Colin W. H.
Abram, Pénélope
Omri, Samy
Cagnone, Gael
Sawmy, Khushnouma Virah
Joyal, Jean-Sébastien
Desjarlais, Michel
Olson, David
Weil, Alexander G.
Lubell, William
Rivera, José Carlos
Chemtob, Sylvain http://orcid.org/0000-0001-7923-5221
Funding for this research was provided by:
Canadian Institutes of Health Research (950-231837)
Article History
Received: 21 September 2020
Accepted: 10 November 2020
First Online: 27 November 2020
Ethics approval and consent to participate
: All animal experiments were approved by the Maisonneuve Rosemont Hospital Animal Care Committee and were performed in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Visual Research.
: Not applicable.
: The corresponding author (SC) holds a patent on a small peptide antagonist of IL-1R, which could be useful in inflammatory ischemic retinopathies, yet this compound remains at the pre-clinical stage and the intellectual property is held by the CHU-Sainte Justine Hospital, Montreal.